As NOA-21, a neoadjuvant window-of-opportunity trial in patients with recurrent IDH1-mutant gliomas [24], INTERCEPT-H3 integrates an immune checkpoint inhibitor to amplify neoepitope-specific T cell responses. The gene discussed is IDH1; the disease is glioma.